Our focus is on developing DMX-1001 (oral noribogaine), a promising investigational therapy for alcohol use disorder, which affects over 29 million people in the U.S.
Transforming Addiction Therapeutics
Welcome to DemeRx. We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction.
Discover how neuroplasticity—the brain’s ability to adapt and change – has the potential to address the underlying issues of substance use disorders.
Every day, we are driven by a steadfast commitment to revolutionize addiction therapeutics and improve outcomes for people battling substance use.